Sir: Delayed hematoma formation following augmentation mammaplasty is a rare complication.1–5 We encountered the largest hematoma ever reported, and the furthest from initial surgery, when a 56-year-old African American woman presented with a 3-month history of left breast swelling. The patient had subglandular silicone breast implants placed in the late 1970s and denied any recent trauma. On examination, the patient had extensive asymmetry, with a very large, firm left breast distended to approximately the size of a basketball (Fig. 1). Mammography and ultrasound showed evidence of implant rupture and a large fluid collection surrounding the implant. Computed tomography identified a well-defined fat plane between the fluid and the pectoralis major muscle (Fig. 2).Fig. 1.: The patient presented with a 3-month history of a slowly enlarging left breast.Fig. 2.: Computed tomographic scan of the chest reveals a large heterogeneous fluid collection within the left breast, a well-demarcated plane between this collection and the pectoralis major muscle, and bilateral implant rupture.During surgical exploration, the implant was found to be ruptured with silicone mixed within the hematoma fluid. In total, 4.5 liters of material was removed from the breast. Open periprosthetic capsulectomy was performed, and biopsy specimens were obtained from thickened areas of the capsule. Results of cultures were negative and pathologic evaluation revealed a ruptured silicone implant, with benign fibroadipose tissue and chronic inflammation. Within the specimen, silicone granulomas with multinucleated giant cell reaction and hemosiderin-laden macrophages were identified. The postoperative course was uneventful, and staged reconstruction is planned. In 1979, Georgiade et al. first reported a hematoma developing in a 25-year-old patient 2.5 years after breast augmentation using saline prostheses containing triamcinolone acetonide.1 During exploration, an eroded capsular artery was found to be actively bleeding, and this was ascribed to the steroid infusion. Follow-up reports attribute late hematoma formation to the erosion of vessels arising from the breast capsule, and various inciting factors have been described, including inflammation, microfracture of the capsule, friction of the implant against the capsule, and trauma.2–5 Our pathologic findings are consistent with inflammation contributing to the development of the hematoma, likely as a reaction to the ruptured silicone implant. Previous case reports describe chronic expanding hematomas developing around various types of implants after a period ranging from 5 months to 22 years; thus, this hematoma is the furthest from time of onset, developing 30 years after augmentation.4 Before this study, the largest hematoma evacuated was 500 ml, whereas in this case, 4.5 liters of fluid was removed, making this the largest collection to date.5 Described treatment of hematomas ranges from close observation to surgical management.2–5 In the setting of hematoma development many years after augmentation without an inciting event, other pathologic findings such as infection, inflammation, and malignancy should be considered. The hematoma requires drainage, and the capsule must be examined for any evidence of persistent bleeding. In addition, the breast and capsule must be inspected for any evidence of malignancy, especially in the setting of reconstruction and prior malignancy. In summary, hematoma formation is a rare complication of breast implantation. Patients presenting with sudden swelling of the breast should be evaluated for infection, malignancy, and late hematoma formation. Imaging studies are useful adjuncts to better characterize breast abnormality, but ultimately surgical exploration is the standard treatment. DISCLOSURE The authors have no financial interest to disclose in relation to the content of this article. Yvonne Rasko, M.D. Department of Surgery Division of Surgical Oncology Michel Saint-Cyr, M.D. Department of Plastic and Reconstructive Surgery Yan Peng, M.D. Department of Pathology Roshni Rao, M.D. Department of Surgery Division of Surgical Oncology University of Texas Southwestern Medical Center Dallas, Texas
Read full abstract